Shicheng Sun

Shicheng Sun

Auto-generated profile, based on publicly available information

Shicheng Sun

Murdoch Children’s Research Institute, The Royal Children’s Hospital, Parkville, Australia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2022 in Nature
Verified
Journal Article
Closed access
PDF file
JGJingyang Guan
Jingyang Guan
GWGuan Wang
Guan Wang
JWJinlin Wang
Jinlin Wang
ZZZhengyuan Zhang
Zhengyuan Zhang
YFYao Fu
Yao Fu
HDHongkui Deng
Hongkui Deng

27 January 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
AMA. Moretti
A. Moretti
LFL. Fonteyne
L. Fonteyne
FGF. Giesert
F. Giesert
PHP. Hoppmann
P. Hoppmann
AMA. B. Meier
A. B. Meier
CKChristian Kupatt
Christian Kupatt

26 April 2019 in Science
Verified
Journal Article
Closed access
PDF file
CXChengang Xiang
Chengang Xiang
YDYuanyuan Du
Yuanyuan Du
GMGaofan Meng
Gaofan Meng
LYLiew Soon Yi
Liew Soon Yi
SSShicheng Sun
Shicheng Sun
HDHongkui Deng
Hongkui Deng
Keep hepatocytes fresh: Freshly isolated primary human hepatocytes (PHHs) quickly lose their identity and function in vitro, limiting their application in modeling infectious liver diseases and screening drugs. Xiang et al. describe a simple and effective five-chemical culture condition that can maintain the mature function of cultured PHHs for an extended period of time. PHHs cultured in this way can support the entire viral life cycle and recapitulate long-term infection of the hepatitis B virus. This system created a useful drug-screening platform for developing new antiviral strategies. Science , this issue p. 399

3 February 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
YDYuanyuan Du
Yuanyuan Du
ZLZhen Liang
Zhen Liang
SWShusen Wang
Shusen Wang
DSDong Sun
Dong Sun
XWXiaofeng Wang
Xiaofeng Wang
HDHongkui Deng
Hongkui Deng

2 September 2024 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
ENElizabeth S. Ng
Elizabeth S. Ng
GSGulcan Sarila
Gulcan Sarila
JLJacky Y. Li
Jacky Y. Li
HEHasindu S. Edirisinghe
Hasindu S. Edirisinghe
RSRitika Saxena
Ritika Saxena
AEAndrew G. Elefanty
Andrew G. Elefanty
Hematopoietic stem cells (HSCs) derived from human induced pluripotent stem cells (iPS cells) have important biomedical applications. We identified differentiation conditions that generate HSCs defined by robust long-term multilineage engraftment in immune-deficient NOD,B6.Prkdc scid Il2rg tm1Wjl/SzJ Kit W41/W41 mice. We guided differentiating iPS cells, as embryoid bodies in a defined culture medium supplemented with retinyl acetate, through HOXA-patterned mesoderm to hemogenic endothelium specified by bone morphogenetic protein 4 and vascular endothelial growth factor (VEGF). Removal of VEGF facilitated an efficient endothelial-to-hematopoietic transition, evidenced by release into the culture medium of CD34+ blood cells, which were cryopreserved. Intravenous transplantation of two million thawed CD34+ cells differentiated from four independent iPS cell lines produced multilineage bone marrow engraftment in 25–50% of immune-deficient recipient mice. These functionally defined, multipotent CD34+ hematopoietic cells, designated iPS cell-derived HSCs (iHSCs), produced levels of engraftment similar to those achieved following umbilical cord blood transplantation. Our study provides a step toward the goal of generating HSCs for clinical translation.

2 March 2021 in Cell Discovery
Verified
Journal Article
Open access
PDF file
YMYantao Ma
Yantao Ma
HXHandan Xie
Handan Xie
XDXiaomin Du
Xiaomin Du
LWLipeng Wang
Lipeng Wang
XJXueqin Jin
Xueqin Jin
HDHongkui Deng
Hongkui Deng
In mammals, many organs lack robust regenerative abilities. Lost cells in impaired tissue could potentially be compensated by converting nearby cells in situ through in vivo reprogramming. Small molecule-induced cell reprogramming offers a temporally flexible and non-integrative strategy for altering cell fate, which is, in principle, favorable for in vivo reprogramming in organs with notoriously poor regenerative abilities, such as the brain. Here, we demonstrate that in the adult mouse brain, small molecules can reprogram astrocytes into neurons. The in situ chemically induced neurons resemble endogenous neurons in terms of neuron-specific marker expression, electrophysiological properties, and synaptic connectivity. Our study demonstrates the feasibility of in vivo chemical reprogramming in the adult mouse brain and provides a potential approach for developing neuronal replacement therapies.